Background/Aims: Investigations of Aβ oligomers in neuropathologically confirmed Alzheimer's disease (AD) are still scarce. We report neurohistopathological and biochemical analyses using antibodies against tau and amyloid β (Aβ) pathology. Methods: Thirty elderly AD patients and 43 age-matched controls with or without deposition of amyloid plaques (AP) were analyzed by immunohistochemistry. In 21 cases with available fresh tissue, Western blots were also performed. Neuropathological analysis included quantitative assessment of neurofibrillary tangles (NFT), AP and Aβ oligomer densities in the mesial temporal cortex (TC). Results: NFT, fibrillar amyloid and Aβ oligomeric deposit densities were significantly higher in AD patients than in controls. There was no relationship between oligomeric Aβ densities and Braak NFT staging scores. Furthermore, Aβ oligomer expression was closely correlated with Aβ plaques in the TC. By Western blot, Aβ oligomers were observed in AD patients, in plaque-free controls, in 1 ‘tangle-only AD' case, as well as in the cerebellum. A band near 55 kDa was the only Western blot signal that was significantly increased in the TC of AD patients compared to controls as well as less expressed in the cerebellum. Conclusion: These results suggest that a putative dodecamer, near 55 kDa, may contribute to AD vulnerability of the TC.

Keywords:
Aβ oligomers, Alzheimer’s disease, Amyloid plaques, Cerebral cortex, Neuropathology, Synaptic loss, Tangles, Temporal cortex, Cerebellum
1.
Ashe KH, Zahs KR: Probing the biology of Alzheimer's disease in mice. Neuron 2010;66:631-645.
2.
Klein WL, Krafft GA, Finch CE: Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 2001;24:219-224.
3.
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al: Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-6453.
4.
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155:853-862.
5.
McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al: Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-866.
6.
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539.
7.
Giannakopoulos P, Bouras C, Hof PR: Clinicopathologic correlates in the oldest-old: commentary on ‘No disease in the brain of a 115-year-old woman'. Neurobiol Aging 2008;29:1137-1139.
8.
Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al: Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003;60:1495-1500.
9.
Mucke L, Selkoe DJ: Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012;2: a006338.
10.
Benilova I, Karran E, De Strooper B: The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012;15:349-357.
11.
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al: Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003;100:10417-10422.
12.
Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ: Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA 2011;108:5819-5824.
13.
Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-112.
14.
Hefti F, Goure WF, Jerecic J, Iverson KS, Walicke PA, Krafft GA: The case for soluble Aβ oligomers as a drug target in Alzheimer's disease. Trends Pharmacol Sci 2013;34:261-266.
15.
Kostylev MA, Kaufman AC, Nygaard HB, Patel P, Haas LT, Gunther EC, et al: Prion-protein-interacting amyloid-beta oligomers of high molecular weight are tightly correlated with memory impairment in multiple Alzheimer mouse models. J Biol Chem 2015;290:17415-17438.
16.
De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, et al: Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 2008;29:1334-1347.
17.
Zempel H, Thies E, Mandelkow E, Mandelkow EM: Aβ oligomers cause localized Ca2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J Neurosci 2010;30:11938-11950.
18.
Larson ME, Lesné SE: Soluble Aβ oligomer production and toxicity. J Neurochem 2012;120(suppl 1):125-139.
19.
Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA, et al: Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging 2011;32:1784-1794.
20.
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al: Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-842.
21.
Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, et al: Monoclonal antibodies that target pathological assemblies of Aβ. J Neurochem 2007;100:23-35.
22.
Velasco PT, Heffern MC, Sebollela A, Popova IA, Lacor PN, Lee KB, et al: Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem Neurosci 2012;3:972-981.
23.
Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, Marutle A: Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging 2012;33:825.e1-e13.
24.
Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al: Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 2013;73:104-119.
25.
Lesné SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, et al: Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain 2013;136:1383-1398.
26.
Giannakopoulos P, Gold G, Kovari E, von Gunten A, Imhof A, Bouras C, et al: Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol 2007;113:1-12.
27.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
28.
Goedert M, Jakes R, Vanmechelen E: Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 1995;189:167-169.
29.
Bussière T, Friend PD, Sadeghi N, Wicinski B, Lin GI, Bouras C, et al: Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. Neuroscience 2002;112:75-91.
30.
Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
31.
Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, et al: Sequence of Aβ-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 2000;59:733-748.
32.
Eder-Colli L, Abad-Estarlich N, Pannetier C, Vallet PG, Walzer C, Elder GA, et al: The presenilin-1 familial Alzheimer's disease mutation P117L decreases neuronal differentiation of embryonic murine neural progenitor cells. Brain Res Bull 2009;80:296-301.
33.
Watt AD, Perez KA, Rembach A, Sherrat NA, Hung LW, Johanssen T, et al: Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples. Acta Neuropathol 2013;125:549-564.
34.
Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-357.
35.
Robakis NK: Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives. Neurobiol Aging 2011;32:372-379.
36.
Kokubo H, Kayed R, Glabe CG, Yamaguchi H: Soluble Aβ oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res 2005;1031:222-228.
37.
Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al: Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004;24:10191-10200.
38.
Liu P, Paulson JB, Forster CL, Shapiro SL, Ashe KH, Zahs KR: Characterization of a novel mouse model of Alzheimer's disease - amyloid pathology and unique β-amyloid oligomer profile. PLoS One 2015;10:e0126317.
39.
Zahs KR, Ashe KH: β-Amyloid oligomers in aging and Alzheimer's disease. Front Aging Neurosci 2013;5:28.
40.
Yasojima K, McGeer EG, McGeer PL: Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 2001;919:115-121.
41.
Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, et al: Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci 2009;29:1977-1986.
42.
Zempel H, Mandelkow EM: Linking amyloid-β and tau: amyloid-β induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener Dis 2012;10:64-72.
43.
Braak H, Del Tredici K: The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain 2015;138:2814-2833.
44.
Chetelat G: Alzheimer disease: Aβ-independent processes - rethinking preclinical AD. Nat Rev Neurol 2013;9:123-124.
45.
Dong S, Duan Y, Hu Y, Zhao Z: Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 2012;1:18.
46.
Moreno-Trevino MG, Castillo-Lopez J, Meester I: Moving away from amyloid β to move on in Alzheimer research. Front Aging Neurosci 2015;7:2.
47.
Pimplikar SW: Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 2009;41:1261-1268.
48.
Schonheit B, Zarski R, Ohm TG: Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging 2004;25:697-711.
49.
Villemagne VL, Okamura N: Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions. Curr Opin Neurobiol 2016;36:43-51.
50.
Giacobini E, Gold G: Alzheimer disease therapy - moving from amyloid-β to tau. Nat Rev Neurol 2013;9:677-686.
51.
Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010;142:387-397.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.